Latest News

F2G bags €50.8m financing to advance olorofim

Aspergillus spores could become dangerous for people with a weakened immune system. © CDC


by tg

UK-Austrian fungal infection specialist F2G Ltd has secured a €50.8m (US $60.8m) financing from new and existing investors.

The €50.8m financing round was led by Cowen Healthcare Investments and includes strong participation from existing investors Novo Holdings, Morningside Ventures, Brace Pharma Capital and Advent Life Sciences.

The Manchester and Vienna-based company announced it will use the proceeds to finance the ongoing Phase IIb proof-of concept study of its antifungal compound olorofim (F901318) and preparatory work for its commercialisation. F901318, a dihydrorotate dehydrogenase (DHODH) blocker, is in a Phase 2b open-label study focussing on rare and resistant life-threatening opportunistic fungal infections, such as invasive aspergillosis, scedosporiosis, lomentosporiosis, fusariosis, scopulariopsosis, and valley fever. Olorofim, F2G’s lead compound from the novel drug class of orotomides that block fungal de novo pyrimidine synthesis, could represent a market opportunity in excess of US$6bn. 

EMA: AZD1222 causes serious rare ADEs

However, the EMA has no idea which component of the cheapest COVID-19 vaccine on the market is supposed to cause the splanchnic leg and sinus vein...

Novel COVID antibody enters clinical testing

In contrast to existing COVID-19 treatments, the safety design of COR-101 is optimised for the treatment of hospitalized COVID-19 patients with...

Pieris in $1.4bn deal with Roche

Under the terms of the agreement that forsees additional $1.4bn in milestones and tiered royalties across multiple programmes, the partners will use...

B.1.1.7 variant associated with higher mortality

Previous reports from British autorities that suggested a 30 to 100% higher mortality of B.1.1.7 than of the previously dominant form in Europe are...

Media hype on Denmark’s decision to halt AZD1222 vaccination

Since Denmark suspended vaccination with AstraZeneca’s bashed Covid-19 vaccine, AZD1222 is facing questions over its safety. Denmark’s...

Roche Phase III study misses COVID-19 endpoint

In the Phase III REMDACTA trial, the Swiss pharma major combined its cytokine storm blocker tocolizumab with Gilead Science’s viral transcription...

Record year for Swiss biotech industry

Driven by the corona crisis, the Swiss biotech ecosystem is thriving as never before. This is evidenced by the Swiss Biotech Report from EY, the...